Updated:
Exact Sciences
Exact Sciences helps eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment. Their tests explore hereditary risks, screen...
Exact Sciences
Exact Sciences helps eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment. Their tests explore hereditary risks, screen for cancer’s presence, and examine genomic alterations after diagnosis to help guide treatment. They aim to transform how cancer is detected, diagnosed, and managed worldwide.
General information
Firm type
Asset Manager
Location
Region
North America
Country
United States
City
Madison
Corporate office
Madison, WI, United States
Principals
Joe Webb
wellness senior manager
Rhonda Jensen
people operations specialist
Colleen Zagone
environmental health and safety specialist
Emily Erbst
senior administrative assistant
Whitney McMasters
regional oncogenomic liaison
Sector focus
Frequently asked questions
What does Exact Sciences' diagnostic portfolio cover?
The company operates across three oncology nodes: screening (Cologuard and Cologuard Plus for colorectal cancer), therapy guidance (Oncotype DX tests for breast, colon, and DCIS recurrence risk and chemotherapy benefit), and precision medicine (OncoExTra for comprehensive genomic profiling of solid tumors). The Riskguard hereditary cancer test, acquired through PreventionGenetics in 2022, adds hereditary risk assessment (per the firm's product pages).
How did the BLUE-C study change the company's screening franchise?
The BLUE-C study, published in 2024, served as the pivotal validation for Cologuard Plus, the next-generation stool-DNA colorectal cancer screening test. The study compared the updated assay against colonoscopy in a large prospective cohort, providing the clinical evidence needed to support FDA submission and large-scale commercial adoption (per the firm's public releases). Results are expected to drive physician adoption rates for the upgraded test.
Which companies are Exact's primary cited competitors?
In screening, the firm competes against colonoscopy providers and other non-invasive stool-based tests, though no single named competitor dominates the labeled indication. In therapy guidance, Agendia (MammaPrint) and Veracyte offer overlapping breast cancer gene-expression tests. For comprehensive genomic profiling, Guardant Health and Foundation Medicine operate larger pan-cancer platforms with broader biomarker panels and established oncologist ordering patterns.
What role does prevention play in the company's product architecture?
Prevention sits upstream of every other business line: Cologuard and Cologuard Plus screen asymptomatic average-risk individuals for colorectal cancer, while the Riskguard test identifies germline mutations that elevate lifetime cancer risk. This creates a testing funnel that can feed patients into the Oncotype DX therapy-guidance franchise and the OncoExTra therapy-selection assay after diagnosis.
Does Exact Sciences operate clinical laboratories itself or outsource testing?
The company operates its own CLIA-certified laboratories, with primary facilities in Madison, Wisconsin. In-source lab operations give it control over turnaround time, assay iteration, and margin structure, though this model requires sustained capital expenditure for capacity expansion as test volumes grow.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: